Allied Minds had invested over $50m in New York University RAM technology spinout Spin Memory, which has decided to liquidate its assets to pay creditors.

GV notched up an exit as cancer therapy developer Monte Rosa Therapeutics priced an upsized initial public offering at the top of its range.

BeiGene helped mRNA therapeutics developer Strand Therapeutics raise $52m while the Afterpay-backed AP Ventures led logistics provider Sendle's $35m series C round.

Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Oshri Kaplan, director, Munich Re Ventures

MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.

Intel Capital-backed customer experience software provider Sprinklr floated below its range in its initial public offering.

Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

Long-term investor Boston Scientific is paying $295m upfront for the 73% of the ablation technology developer it does not own.